

InVivo tanks on push-back for spinal injury trial

Mass Device

InVivo shares lose nearly half their value after the company announces a delay to its spinal treatment clinical trials.



[InVivo Therapeutics](#) [1] (OTC:[NVIV](#) [2]) announced a push-back on its time-lines for enrollment in a clinical trial examining its spinal cord injury treatment, a move that brought NVIV shares down by nearly half today.

InVivo announced that, under the terms of its FDA investigational device exemption, each trial patient must be followed for 3 months and the company must win agency approval before enrolling the next, meaning it will take InVivo an estimated 21 months to enroll its 5 patients.

Source URL (retrieved on 01/28/2015 - 5:25am):

<http://www.mdtmag.com/news/2013/08/invivo-tanks-push-back-spinal-injury-trial>

Links:

[1] <http://www.massdevice.com/company/invivo-therapeutics-corp>

[2] <http://www.google.com/finance?q=OTC%3ANVIV>